JANX NASDAQ
Janux Therapeutics, Inc.
1W: +0.3%
1M: +4.1%
3M: +15.4%
YTD: +26.4%
1Y: -30.7%
3Y: +155.7%
5Y: -19.8%
$17.26
+0.57 (+3.42%)
Pre-Market: $17.36 (+0.10, +0.58%)
Weekly Expected Move ±6.3%
$15
$16
$17
$18
$19
Credit Risk of going bust: higher than 54% of companies Debt: 2.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.06 (down 99.6%), Janux Therapeutics, Inc. would be worth roughly what it owes.
Total debt $21.0M against a stock market value of $1.06B.
Distance to default 4.76 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $10.5M (short-term plus half of long-term), stock volatility 90.4%; Altman Z'' 16.27. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.06 (down 99.6%), Janux Therapeutics, Inc. would be worth roughly what it owes.
Total debt $21.0M against a stock market value of $1.06B.
Distance to default 4.76 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $10.5M (short-term plus half of long-term), stock volatility 90.4%; Altman Z'' 16.27. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
Articles (1)
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (42)
Ensign Group (ENSG) Beats Q3 Earnings Estimates
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
State Street Corp Boosts Stake in Janux Therapeutics, Inc. $JANX
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
Janux Therapeutics GAAP EPS of -$0.35 misses by $0.09, revenue of $10.27M misses by $7.67M
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know
Here's Why You Should Add JANX Stock to Your Portfolio Now
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%
Janux Therapeutics Halts Early Stage Cancer Program In 'Prudent' Move
Janux ends development of Tumor Activated T Cell Engager asset
Will Acute Care Strength Help Universal Health Offset Q1 Rising Costs?
Will Higher Costs & Lower Occupancy Impact HCA's Q1 Earnings?
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of “Moderate Buy” from Brokerages
Will Health Benefits Weakness Drag Elevance's Q1 Earnings?
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
HC Wainwright Has Optimistic Outlook of JANX Q1 Earnings
Janux Therapeutics GAAP EPS of -$0.51 beats by $0.16
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Lowest Quant ranked small-cap stocks with positive EPS surprises
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
JANX Enters Global Oncology Collaboration With BMY, Stock Rises
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of “Moderate Buy” from Brokerages
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week Low – Time to Sell?
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
32,772 Shares in Janux Therapeutics, Inc. $JANX Purchased by Capital Fund Management S.A.
Options Exercise: Janux Executive Sells 16,665 Shares for $501,000
Janux Therapeutics Stock Hits 52-Week Low After Trial Update
Janux dives as gaps in prostate cancer study data worry investors
Janux Therapeutics Stock Craters After ‘Positive' Cancer Drug Trial Data. Why It's Down 41%.
Ensign Peak Advisors Inc Decreases Holdings in Janux Therapeutics, Inc. $JANX
Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC